NCT02605863View on ClinicalTrials.gov

Enzalutamide for Bladder Cancer Chemoprevention

PHASE2TerminatedINTERVENTIONAL

Enrollment

1

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

February 28, 2018

Study Completion Date

February 28, 2018

Conditions

Bladder Cancer

Interventions

DRUG

Enzalutamide

160 mg by mouth daily for 12 months

Trial Locations (1)

14642

University of Rochester, Rochester

Sponsors

Collaborators (1)

Astellas Pharma Inc

All Listed Sponsors

collaborator

Astellas Pharma Inc

INDUSTRY

lead

University of Rochester

OTHER

NCT02605863 - Enzalutamide for Bladder Cancer Chemoprevention | Biotech Hunter | Biotech Hunter